=====

Why Are Moderna Executives Dumping Their Stock?

Story at-a-glance

- Results from Moderna’s Phase 1 human trial revealed the 100-mcg dose vaccine — which had a 100% side effect ratio after the second dose — is proceeding to Phase 3 trial assessment

- Moderna has no legal rights to a key patent for its vaccine delivery system. Moderna sought to invalidate the patent for lipid nanotechnology owned by Arbutus Biopharma but lost the challenge at the end of July 2020

- Executives at Moderna have cashed in stock options, raking in about $90 million in personal profits since January. Two Moderna executives have now sold off all of their stock holdings in the company, and its general counsel has sold nearly all of hers

- AstraZeneca has temporarily halted its Phase 3 vaccine trials due to “a suspected serious and unexpected adverse reaction” in a British participant

- AstraZeneca did not divulge the nature of the adverse reaction, but an anonymous source claims the trial participant was found to have transverse myelitis, an inflammatory condition that affects the spinal cord and is frequently triggered by viral infections

https://articles.mercola.com/sites/articles/archive/2020/09/21/coronavirus-vaccine-patent.aspx?cid_source=dnl&cid_medium=email&cid_content=art1HL&cid=20200921Z1&mid=DM660562&rid=969619187

*************************************************************